diagnostic utility of procalcitonin in children with infectious complications during chemotherapy-induced neutropenia: single center experience, literature review

Background. Infectious complications cause significant mortality in children with oncological diseases during chemotherapy-induced neutropenia. The absence of sensitive and specific signs and symptoms of infectious conditions as well as its microbiological identification, leads to inappropriate antibiotic exposure. The use of laboratory biomarkers (procalcitonin (PCT) and C-reactive protein (CRP)) may be helpful for differential diagnostics of inflammatory conditions and for rational antimicrobial therapy.

Objective: to assess the current value of PCT as an additional marker for differentiating inflammatory conditions in children with chemotherapy-induced neutropenia.

Materials and methods. We presented the analysis of infectious complications in pediatric patients with oncological and onco- / hematological diseases between 2017–2020 (54 patients from 2 mnths – 17 years). PCT and CRP with clinical and instrumental diagnostic data were used for differential diagnosis of fever and development of antimicrobial therapy decision rules. Literature review concerning the discussed theme from 2006–2018 was done.

Results. Eighty-five infectious episodes in 36 months were registered, among them 42 in pts with onco- / hematological diseases and 43 – with solid tumors. In the group of bacterial infectious complications mean CRP and PCT values were significantly higher than in group of nonbacterial, moreover the discriminative value was higher for PCT. We revealed the correlation between severity of infectious complications and values of markers of acute-phase reactions. In case of non-severe bacterial complications and other types of infections significant difference was revealed only for PCT mean values.

Conclusion. Specificity of PCT concentration in bacterial infections exceeds that of CRP, which confirms the hypothesis of advantages in using PCT as differential marker of inflammatory conditions in children with malignancies. 

1. Simon A., Ammann R., Bode U. et al. Healthcare­associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008;8:70. DOI: 10.1186/1471­2334­8­70.

2. Schuetz P., Albrich W., Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine 2011;9:107. DOI: 10.1186/1741­7015­9­107.

3. Roberts R., Hota B., Ahmad I. et al. Hospital and societal costs of antimicrobial­resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49(8): 1175–84. DOI: 10.1086/605630.

4. Leli C., Ferranti M., Moretti A. et al. Procalcitonin levels in gram­positive, gram­negative, and fungal bloodstream infections. Disease Markers 2015:2015:701480. DOI: 10.1155/2015/701480.

5. Roques М., Chretien M., Favenne C. et al. Evolution of procalcitonin, C­reactive protein and fibrinogen levels in neutropenic leukemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses 2016;59(6):383–90. DOI: 10.1111/myc.12487.

6. Schuetz P., Suter­Widmer I., Chaudri A. et al. Prognostic value of procalcitonin in community­acquired pneumonia. Eur Resp J 2011;37(2):384–92. DOI: 10.1183/09031936.00035610.

7. Schuetz P., Albrich W., Christ­Crain M. et al. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8(5):575–87. DOI: 10.1586/eri.10.25.

8. Sakr Y., Sponholz C., Tuche F. et al. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008;36(5):396–407. DOI: 10.1007/s15010­008­7374­y.

9. Christ­Crain M., Stolz D., Bingisser R. et al. Procalcitonin guidance of antibiotic therapy in community­acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174(1): 4–93. DOI: 10.1164/rccm.200512­1922OC.

10. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28(3):285–91. DOI: 10.3904/kjim.2013.28.3.285.

11. Heyland D.K., Johnson A.P., Reynolds S.C., Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39(7):1792–9. DOI: 10.1097/CCM.0b013e31821201a5.

12. Schuetz P., Chiappa V., Briel M., Greenwald J. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171(15):1322–31. DOI: 10.1001/archinternmed.2011.318.

13. Lyskina G.A., Dronov I.A., Tugarinova G.V., Fomenko T.M. Blood procalcitonin level in pediatric practice. Pediatriya = Pediatrics 2006;85(4):32–44. (In Russ.).

14. Klastersky J., de Naurois J., Rolston K. et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;27(Suppl 5):v111–8. DOI: 10.1093/annonc/mdw325.

15. Hatzistilianou M., Rekleity A., Athanassiadou F. et al. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med 2007;30(2):E75–85. DOI: 10.25011/cim.v30i2.983.

16. Hemming V., Jakes A., Shenton G., Phillips B. Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia. BMC Pediatr 2017;17(1):2. DOI: 10.1186/s12887­016­0766­8.

17. Schuttrumpf S., Binder L., Hagemann T. et al. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C­reactive protein plasma concentrations. Clin Infect Dis 2006;43(4):468–73. DOI: 10.1086/505394.

18. Marková M., Brodská H., Malíčková K. et al. Substantially elevated C­reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Support Care Cancer 2013;21(10): 2733–42. DOI: 10.1007/s00520­013­1844­1.

19. Shuetz P., Christ­Crain M., Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections – hope for hype? Swiss Med Wkly 2009;139(23–24):318–26. DOI: smw­12584.

20. Wirz Y., Meier M.A., Bouadma L. et al. Effect of procalcitonin­guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient­level meta­analysis of randomized trials. Crit Care 2018;22(1):191. DOI: 10.1186/s13054­018­2125­7.